Navigation Links
Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2013 First Quarter Financial Results
Date:5/10/2013

THE WOODLANDS, Texas, May 10, 2013 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three months  ended March 31, 2013.

"In the first quarter of 2013, we continued to progress our clinical pipeline on multiple fronts. Most notably, we initiated a Phase 2 trial of LX4211, our dual inhibitor of SGLT1 and SGLT2, in patients with type 1 diabetes", said Dr. Arthur T. Sands, president and chief executive officer of Lexicon. "We continue to see opportunities for LX4211 as a potential therapy for a broad spectrum of diabetic conditions including type 1 and type 2 diabetes and diabetes with renal impairment."

Progress in Clinical Pipeline

  • LX4211:  Lexicon is proceeding with preparations for the initiation of Phase 3 clinical trials of LX4211 in type 2 diabetes.  Lexicon also initiated a Phase 2 clinical trial of LX4211 in type 1 diabetes and continues to enroll patients in a clinical trial evaluating LX4211 in type 2 diabetes patients with renal impairment.  LX4211 is a dual inhibitor of sodium-glucose transporter 2 (SGLT2), which is responsible for most of the glucose reabsorption performed by the kidney, and sodium-glucose transporter 1 (SGLT1), which is responsible for glucose and galactose absorption in the gastrointestinal tract and, to a lesser degree than SGLT2, glucose reabsorption in the kidney.
  • Telotristat etiprate (LX1032):  Lexicon continues to enroll pat
    '/>"/>

  • SOURCE Lexicon Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine technology :

    1. Lexicon Advances LX4211 In Type 1 Diabetes Phase 2 Trial
    2. Lexicon to Report First Quarter Financial Results on May 10, 2013
    3. Lexicon To Present At The Needham Healthcare Conference
    4. Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2012 Fourth Quarter And Full Year Financial Results
    5. Lexicon To Present At The BIO CEO & Investor Conference
    6. Lexicon Pharmaceuticals To Present At The Piper Jaffray Annual Healthcare Conference
    7. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2012 Third Quarter Results
    8. Lexicon to Provide Third Quarter 2012 Financial Results
    9. Lexicon Pharmaceuticals To Present At The Stifel Nicolaus 2012 Healthcare Conference
    10. Lexicon Pharmaceuticals Reports Preliminary Results From Two Phase 1 Studies
    11. Lexicon Pharmaceuticals To Present At The Wedbush PacGrow 2012 Management Access Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/27/2015)... 27, 2015  PTC Therapeutics, Inc. (NASDAQ: ... financial results for the fourth quarter and full year ... a transformative year for PTC. We are now a ... RNA-targeted therapies in the rare disease space," stated Stuart ... "We are proud to bring the first treatment for ...
    (Date:2/27/2015)... , February 27, 2015 ... bahnbrechendes Überwachungssystem für kongestive Herzinsuffizienz (CHF) in ...     ... ein neuartiges Herzüberwachungssystem für Patienten mit kongestiver ... dass sie ein Finanzierungsvorhaben über 5 Mio. ...
    (Date:2/27/2015)... TORONTO , Feb. 27, 2015  Bionik Laboratories ... (the "Company"), announced today that it acquired Bionik Laboratories, ... Laboratories"), and completed the sale to qualified accredited investors ... for aggregate gross proceeds of approximately $6.2 million. Shares ... quoted on the OTC Markets under the symbol "DWTPD" ...
    Breaking Medicine Technology:PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 10PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 11Vectorious Medical Technologies schließt Finanzierungsvorhaben über 5 Mio. USD ab 2Bionik Laboratories Raises $6.2 Million 2Bionik Laboratories Raises $6.2 Million 3
    (Date:2/28/2015)... 28, 2015 In recent years Medical Marijuana ... practicing physicians as a way for them to expand their ... Cannabis as medicine. Since the FDA still lists Cannabis as ... available to licensed physicians that can help guide them ... Deborah Malka in Santa Cruz, CA is a leader ...
    (Date:2/28/2015)... Portland, OR (PRWEB) February 28, 2015 ... Duncan Fletcher of Game Change ... and Shannon Leinert about the benefits of athlete development ... underscores some of the unique challenges that athletes face ... on-field and future success. , Fletcher became involved in ...
    (Date:2/28/2015)... 2015 With their commitment to achieving ... an additional exercise to their already robust library of ... most commonly known as, is often performed on a ... executed in a relatively safe manner and can be ... The full description of “Rope Pulls” is located in ...
    (Date:2/28/2015)... 28, 2015 The Classic Denture ... a new special. Throughout all of March patients ... , This service can help overall mouth ... pain. Patients may notice certain symptoms that suggest the ... These symptoms include: , 1.    Pain, clicking, and popping in ...
    (Date:2/28/2015)... Mew and Company, a Vancouver corporate tax ... business consulting services in addition to a variety of ... succession planning. Company finances are a complicated matter that ... of this, complex Canadian tax laws can make it ... result, Mew and Company works to advise their clients ...
    Breaking Medicine News(10 mins):Health News:Reputable Cannabis Doctor In Santa Cruz and Monterey Joins the Medical Cannabis Network 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 3Health News:Classic Denture Center in Portland Oregon is Offering March Discount 2Health News:Vancouver Corporate Tax Accountants Now Provide Business Consulting Services 2
    ... BELLEVUE, Wash., Sept. 11 The Citizens,Committee for the ... with,Oklahoma Sen. Tom Coburn that there is a serious ... Suicide Prevention Act -- that could,ultimately prevent military veterans ... defend., The problem, as pointed out by Sen. ...
    ... Thanks to a $1.6 million grant from the Welch ... launching a new initiative to develop innovative computational and ... drugs and molecular tools for biomedical science. , The ... Gulf Coast Consortium for Chemical Genomics (GCC CG) to ...
    ... with the breast cancer susceptibility gene BRCA1 often remove ... they believe fuels cancer growth. Yet they also know ... ovarian cancer that might develop. That paradox has led ... involved in cancer development and whether removal of ovaries ...
    ... Inc. (Pink Sheets: MSITF) wishes to announce that it has,completed ... Hepatitis C,test kit in Europe. Completion of this testing will ... EU approval would allow the Company to expand its ... It is anticipated that,when EU approval is received that it ...
    ... Sept. 11 Responding to a lawsuit by ... national medical,licensing examination, the National Board of Medical ... the needs of breastfeeding mothers as well as,other ... first priority for this test, accepted as evidence ...
    ... treatment, reseachers say , TUESDAY, Sept. 11 (HealthDay News) ... believe they may have found the disease,s genetic on/off ... to the development of better treatments, the team said. ... mouse model for schizophrenia by inserting the mutant Disrupted-In-Schizophrenia ...
    Cached Medicine News:Health News:CCRKBA Backs Sen. Coburn's Opposition to Tenets of H.R. 327 2Health News:Welch Foundation gives $1.6 million for drug discovery research 2Health News:Welch Foundation gives $1.6 million for drug discovery research 3Health News:New clues to breast cancer development in high-risk women 2Health News:New clues to breast cancer development in high-risk women 3Health News:New clues to breast cancer development in high-risk women 4Health News:Medical Services International Inc. Completes Testing for European Union (EU) Application 2Health News:Public Health and Need for Consistent Standards Preclude Exception for Breastfeeding Mother in National Medical Licensing Test 2Health News:Schizophrenia Gene May Have On/Off Switch 2
    VascoScrew is a unipolar permanent pacing lead with a fixed screw a double flanch for permanent pacing. Due to latest technologies, VascoScrew D10/60 M is compatible to all pacemaker-cavities with th...
    VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...
    VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...
    The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),...
    Medicine Products: